153 related articles for article (PubMed ID: 10512614)
21. Dipeptidyl peptidase-4 greatly contributes to the hydrolysis of vildagliptin in human liver.
Asakura M; Fujii H; Atsuda K; Itoh T; Fujiwara R
Drug Metab Dispos; 2015 Apr; 43(4):477-84. PubMed ID: 25597851
[TBL] [Abstract][Full Text] [Related]
22. ASP8497 is a novel selective and competitive dipeptidyl peptidase-IV inhibitor with antihyperglycemic activity.
Matsuyama-Yokono A; Tahara A; Nakano R; Someya Y; Nagase I; Hayakawa M; Shibasaki M
Biochem Pharmacol; 2008 Jul; 76(1):98-107. PubMed ID: 18468582
[TBL] [Abstract][Full Text] [Related]
23. 3-[2-((2S)-2-cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes.
Coumar MS; Chang CN; Chen CT; Chen X; Chien CH; Tsai TY; Cheng JH; Wu HY; Han CH; Wu SH; Huang YW; Hsu T; Hsu LJ; Chao YS; Hsieh HP; Jiaang WT
Bioorg Med Chem Lett; 2007 Mar; 17(5):1274-9. PubMed ID: 17194587
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of dipeptidyl peptidase IV by novel inhibitors with pyrazolidine scaffold.
Cheon HG; Kim SS; Kim KR; Rhee SD; Yang SD; Ahn JH; Park SD; Lee JM; Jung WH; Lee HS; Kim HY
Biochem Pharmacol; 2005 Jul; 70(1):22-9. PubMed ID: 15893294
[TBL] [Abstract][Full Text] [Related]
25. (2S,4S)-1-[2-(1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.
Yeh TK; Tsai TY; Hsu T; Cheng JH; Chen X; Song JS; Shy HS; Chiou MC; Chien CH; Tseng YJ; Huang CY; Yeh KC; Huang YL; Huang CH; Huang YW; Wang MH; Tang HK; Chao YS; Chen CT; Jiaang WT
Bioorg Med Chem Lett; 2010 Jun; 20(12):3596-600. PubMed ID: 20483603
[TBL] [Abstract][Full Text] [Related]
26. High-resolution structure of human apo dipeptidyl peptidase IV/CD26 and its complex with 1-[([2-[(5-iodopyridin-2-yl)amino]-ethyl]amino)-acetyl]-2-cyano-(S)-pyrrolidine.
Oefner C; D'Arcy A; Mac Sweeney A; Pierau S; Gardiner R; Dale GE
Acta Crystallogr D Biol Crystallogr; 2003 Jul; 59(Pt 7):1206-12. PubMed ID: 12832764
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of human immunodeficiency virus type 1 infection in a T-cell line (CEM) by new dipeptidyl-peptidase IV (CD26) inhibitors.
Jiang JD; Wilk S; Li J; Zhang H; Bekesi JG
Res Virol; 1997; 148(4):255-66. PubMed ID: 9272576
[TBL] [Abstract][Full Text] [Related]
28. cis-2,5-dicyanopyrrolidine inhibitors of dipeptidyl peptidase IV: synthesis and in vitro, in vivo, and X-ray crystallographic characterization.
Wright SW; Ammirati MJ; Andrews KM; Brodeur AM; Danley DE; Doran SD; Lillquist JS; McClure LD; McPherson RK; Orena SJ; Parker JC; Polivkova J; Qiu X; Soeller WC; Soglia CB; Treadway JL; VanVolkenburg MA; Wang H; Wilder DC; Olson TV
J Med Chem; 2006 Jun; 49(11):3068-76. PubMed ID: 16722626
[TBL] [Abstract][Full Text] [Related]
29. Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.
McKillop AM; Duffy NA; Lindsay JR; Green BD; Patterson S; O'Harte FP; Bell PM; Flatt PR
Eur J Endocrinol; 2009 Dec; 161(6):877-85. PubMed ID: 19755410
[TBL] [Abstract][Full Text] [Related]
30. Fluoro-olefins as peptidomimetic inhibitors of dipeptidyl peptidases.
Van der Veken P; Senten K; Kertèsz I; De Meester I; Lambeir AM; Maes MB; Scharpé S; Haemers A; Augustyns K
J Med Chem; 2005 Mar; 48(6):1768-80. PubMed ID: 15771423
[TBL] [Abstract][Full Text] [Related]
31. Discovery, structure-activity relationship, and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitors.
Pei Z; Li X; Longenecker K; von Geldern TW; Wiedeman PE; Lubben TH; Zinker BA; Stewart K; Ballaron SJ; Stashko MA; Mika AK; Beno DW; Long M; Wells H; Kempf-Grote AJ; Madar DJ; McDermott TS; Bhagavatula L; Fickes MG; Pireh D; Solomon LR; Lake MR; Edalji R; Fry EH; Sham HL; Trevillyan JM
J Med Chem; 2006 Jun; 49(12):3520-35. PubMed ID: 16759095
[TBL] [Abstract][Full Text] [Related]
32. Medicinal Chemistry of Incretin Mimetics and DPP-4 Inhibitors.
Zettl H; Schubert-Zsilavecz M; Steinhilber D
ChemMedChem; 2010 Feb; 5(2):179-85. PubMed ID: 20029928
[No Abstract] [Full Text] [Related]
33. Lead optimization of [(S)-gamma-(arylamino)prolyl]thiazolidine focused on gamma-substituent: Indoline compounds as potent DPP-IV inhibitors.
Sakashita H; Akahoshi F; Yoshida T; Kitajima H; Hayashi Y; Ishii S; Takashina Y; Tsutsumiuchi R; Ono S
Bioorg Med Chem; 2007 Jan; 15(2):641-55. PubMed ID: 17113301
[TBL] [Abstract][Full Text] [Related]
34. Discovery of C-(1-aryl-cyclohexyl)-methylamines as selective, orally available inhibitors of dipeptidyl peptidase IV.
Namoto K; Sirockin F; Ostermann N; Gessier F; Flohr S; Sedrani R; Gerhartz B; Trappe J; Hassiepen U; Duttaroy A; Ferreira S; Sutton JM; Clark DE; Fenton G; Beswick M; Baeschlin DK
Bioorg Med Chem Lett; 2014 Feb; 24(3):731-6. PubMed ID: 24439847
[TBL] [Abstract][Full Text] [Related]
35. ASP4000, a slow-binding dipeptidyl peptidase 4 inhibitor, has antihyperglycemic activity of long duration in Zucker fatty rats.
Tanaka-Amino K; Matsumoto K; Hatakeyama Y; Takakura S; Mutoh S
Acta Diabetol; 2010 Mar; 47(1):43-8. PubMed ID: 19238312
[TBL] [Abstract][Full Text] [Related]
36. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
Akarte AS; Srinivasan BP; Gandhi S
Biochem Pharmacol; 2012 Jan; 83(2):241-52. PubMed ID: 22015634
[TBL] [Abstract][Full Text] [Related]
37. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
Green BD; Flatt PR; Bailey CJ
Diab Vasc Dis Res; 2006 Dec; 3(3):159-65. PubMed ID: 17160910
[TBL] [Abstract][Full Text] [Related]
38. [(S)-gamma-(Arylamino)prolyl]thiazolidine compounds as a novel series of potent and stable DPP-IV inhibitors.
Sakashita H; Akahoshi F; Kitajima H; Tsutsumiuchi R; Hayashi Y
Bioorg Med Chem; 2006 Jun; 14(11):3662-71. PubMed ID: 16460948
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog.
Edgerton DS; Johnson KM; Neal DW; Scott M; Hobbs CH; Zhang X; Duttaroy A; Cherrington AD
Diabetes; 2009 Jan; 58(1):243-9. PubMed ID: 18840785
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and biological evaluation of pyrrolidine-2-carbonitrile and 4-fluoropyrrolidine-2-carbonitrile derivatives as dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.
Wang J; Feng Y; Ji X; Deng G; Leng Y; Liu H
Bioorg Med Chem; 2013 Dec; 21(23):7418-29. PubMed ID: 24153396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
